GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Asset Turnover

GSTC (GlobeStar Therapeutics) Asset Turnover : 0.00 (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. GlobeStar Therapeutics's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. GlobeStar Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was $0.12 Mil. Therefore, GlobeStar Therapeutics's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. GlobeStar Therapeutics's annualized ROE % for the quarter that ended in Jun. 2024 was 51.20%. It is also linked to ROA % through Du Pont Formula. GlobeStar Therapeutics's annualized ROA % for the quarter that ended in Jun. 2024 was -682.76%.


GlobeStar Therapeutics Asset Turnover Historical Data

The historical data trend for GlobeStar Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Asset Turnover Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlobeStar Therapeutics's Asset Turnover

For the Biotechnology subindustry, GlobeStar Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Asset Turnover falls into.



GlobeStar Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

GlobeStar Therapeutics's Asset Turnover for the fiscal year that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Sep. 2023 )/( (Total Assets (A: Sep. 2022 )+Total Assets (A: Sep. 2023 ))/ count )
=0/( (0.01+0)/ 1 )
=0/0.01
=0.00

GlobeStar Therapeutics's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=0/( (0.148+0.084)/ 2 )
=0/0.116
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


GlobeStar Therapeutics  (OTCPK:GSTC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

GlobeStar Therapeutics's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-0.792/-1.547
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.792 / 0)*(0 / 0.116)*(0.116/ -1.547)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.075
=ROA %*Equity Multiplier
=-682.76 %*-0.075
=51.20 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

GlobeStar Therapeutics's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-0.792/0.116
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.792 / 0)*(0 / 0.116)
=Net Margin %*Asset Turnover
= %*0
=-682.76 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


GlobeStar Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550